Dr. Cohen's primary research interests are in the areas of hypertension and chronic kidney disease. She focuses on the application of epidemiologic and pharmacoepidemiologic methods to better understand physiology-driven pharmacologic effects of antihypertensive medications in complex and high-risk disease states. Dr. Cohen has led several studies that evaluate the accuracy and predictive value of out-of-office blood pressure measurement. She has also led and contributed to a number of studies that evaluate disparities in access to care and long-term outcomes in high-risk patients with chronic kidney disease. 

Dr. Cohen is a faculty member in the Renal-Electrolyte and Hypertension Division in the Department of Medicine. She is currently the principal investigator of a K23 and an R01 grant funded by the National Heart Lung and Blood Institute and co-principal investigator of the multi-center Randomized Elimination or ProLongation of Angiotensin Converting Enzyme inhibitors and angiotensin receptor blockers in Coronavirus Disease 2019 (REPLACE COVID) trial, in which she serves as chair of the Data Coordinating Center. She is also a coinvestigator of the Chronic Renal Insufficiency Cohort (CRIC) Study at the Scientific Data Coordinating Center at the University of Pennsylvania and co-chair of the CRIC Blood Pressure Working Group.